November 2011 
Volume 41  Number 11
Pages 26 - 26
  PDF Version Available!

According to the FDA, dosages of the selective serotonin reuptake inhibitor citalopram shouldn't exceed 40 mg/day because it can cause cardiac conduction abnormalities. Higher doses of this antidepressant medication can trigger dose-dependent QT interval prolongation, possibly leading to life-threatening dysrhythmias such as torsade de pointes. Patients with underlying heart disease (such as heart failure or bradydysrhythmias) and those predisposed to hypomagnesemia and hypokalemia are at particular risk.Labeling for citalopram has been revised to reflect this new recommendation. Previously, the label stated that certain patients may require 60 mg/day, but studies haven't shown a treatment benefit at doses over 40 mg/day. Healthcare providers are encouraged to report any adverse reactions related to the use of citalopram to the FDA's MedWatch Safety Information and Adverse Event Reporting Program.Source: U.S. Food and Drug Administration. Celexa (citalopram hydrobromide): Drug Safety Communication-Abnormal

Purchase Now !

To purchase this item, follow the instructions below. If you’re not already logged in, be sure to enter your login information below to ensure that your item is saved to your File Drawer after you purchase it.

Not a member? Join now for Free!

1) If you're not already logged in, enter your information below to save this item in your File Drawer for future viewing.

User name:


Forgot your user name or password?
2)  If you have a coupon or promotional code, enter it
here.(If not, just click Continue.

Digital Coupon: (optional)

3)  Click Continue to go to the next screen, where
you'll enter your payment details.

jQuery UI Accordion - Default functionality

For life-long learning and continuing professional development, come to Lippincott's NursingCenter.

Nursing Jobs Plus
Featured Jobs
Recommended CE Articles Recommended Nursing Articles

What internal motivators drive RNs to pursue a BSN?
Nursing2014 , October 2014
Free access will expire on November 24, 2014.

Breast Cancer Risk Assessment in Primary Care
MCN, The American Journal of Maternal/Child Nursing, September/October 2014
Free access will expire on November 10, 2014.

Nurses spurring innovation
Nursing Management, October 2014
Free access will expire on November 10, 2014.

More Recommended Articles

Subscribe to Recommended Articles

Evidence Based Practice Skin Care Network NursingCenter Quick Links What’s Trending Events